Terms: = Bone cancer AND DDB2, Q92466, 1643, ENSG00000134574, FLJ34321 AND Treatment
5 results:
1. Circulating biosignatures in multiple myeloma and their role in multidrug resistance.
Krishnan SR; Bebawy M
Mol Cancer; 2023 Apr; 22(1):79. PubMed ID: 37120508
[TBL] [Abstract] [Full Text] [Related]
2. The CtBP1-HDAC1/2-IRF1 transcriptional complex represses the expression of the long noncoding RNA GAS5 in human osteosarcoma cells.
Zhang X; Du K; Lou Z; Ding K; Zhang F; Zhu J; Chang Z
Int J Biol Sci; 2019; 15(7):1460-1471. PubMed ID: 31337976
[TBL] [Abstract] [Full Text] [Related]
3. [Clinical study of intensity modulated radiotherapy and three-dimensional conformal radiotherapy with three-dimensional brachytherapy and concurrent chemotherapy for patients with advanced cervical cancer].
Du XX; Yang H; Zhang HJ; Li LA; Fan WS; Meng YG
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):679-686. PubMed ID: 29060966
[No Abstract] [Full Text] [Related]
4. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Chi KN; Ellard SL; Hotte SJ; Czaykowski P; Moore M; Ruether JD; Schell AJ; Taylor S; Hansen C; Gauthier I; Walsh W; Seymour L
Ann Oncol; 2008 Apr; 19(4):746-51. PubMed ID: 18056648
[TBL] [Abstract] [Full Text] [Related]
5. [The value of positron emission tomography (PET) in the treatment of patients with cancer of unknown primary (CUP)].
Rades D; Kühnel G; Wildfang I; Börner AR; Knapp W; Karstens JH
Strahlenther Onkol; 2001 Oct; 177(10):525-9. PubMed ID: 11680017
[TBL] [Abstract] [Full Text] [Related]
